0.677

3.04% +0.02

After Hours: .7665 0.0895 +13.22%

Petros Pharmaceuticals Inc (PTPI)

Overview News Price History Financials Discussions Forecast Stock Split

Petros Pharmaceuticals Inc stock is currently priced at $0.677, with a 24-hour trading volume of 117.86K. It has seen a +3.04% increased in the last 24 hours and a -36.73% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.6582 pivot point. If it approaches the $0.6784 resistance level, significant changes may occur.

Previous Close:

$0.657

Open:

$0.675

24h Volume:

117.86K

Market Cap:

$4.65M

Revenue:

$6.98M

Net Income/Loss:

$-12.70M

P/E Ratio:

-0.0636

EPS:

-10.64

Net Cash Flow:

$-6.94M

1W Performance:

+5.80%

1M Performance:

-36.73%

6M Performance:

-52.32%

1Y Performance:

-83.16%

1D Range:

$0.665

$0.71

52W Range:

$0.602

$5.2399

Petros Pharmaceuticals Inc Stock (PTPI) Company Profile

Name

Petros Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

973 242 0005

Address

1185 Avenue of the Americas, Suite 249, New York

Employee

Twitter

Next Earnings Date

Latest SEC Filings

PTPI's Discussions on Twitter

Petros Pharmaceuticals Inc Stock (PTPI) Latest News

Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Benzinga

Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Benzinga

Petros Pharmaceuticals Inc Stock (PTPI) Financials Data

Petros Pharmaceuticals Inc (PTPI) Revenue 2024

PTPI reported a revenue (TTM) of $6.98 million for the quarter ending September 30, 2023, a +61.43% rise year-over-year.

Petros Pharmaceuticals Inc (PTPI) Net Income 2024

PTPI net income (TTM) was -$12.70 million for the quarter ending September 30, 2023, a +47.08% increase year-over-year.

Petros Pharmaceuticals Inc (PTPI) Cash Flow 2024

PTPI recorded a free cash flow (TTM) of -$6.94 million for the quarter ending September 30, 2023, a +64.48% increase year-over-year.

Petros Pharmaceuticals Inc (PTPI) Earnings per Share 2024

PTPI earnings per share (TTM) was -$6.20 for the quarter ending September 30, 2023, a +58.94% growth year-over-year.

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.